Mammalian Fusion Proteins: Partner Selection, Placement and Removal

June 20, 2022

min read

A fusion partner can support recombinant protein expression, solubility, purification, detection, or in vivo exposure. In mammalian cell expression, Fc and human serum albumin are common candidates when the protein of interest requires a larger, secretion-compatible partner or a strategy intended to influence circulation behavior.

The partner, orientation, linker, cleavage site, and removal plan should be designed together. Their effects are target-dependent, so a small construct panel and matched analytical readouts are often more informative than selecting one format from general expectations alone.

Molecular structure representing a mammalian fusion protein

What Is a Fusion Protein?

A fusion protein is a recombinant polypeptide in which the coding sequences for two or more protein components are joined into one expression construct. A partner may serve as a purification handle, improve soluble or secreted recovery, alter molecular size, provide a functional domain, or support an intended in vivo property. [1,2]

The fusion format can also change folding, oligomeric state, steric accessibility, receptor binding, or activity. The design should therefore be evaluated as a new molecular entity rather than assumed to behave as the unfused target.

Fusion Protein Expression in Mammalian Cells

Mammalian expression can support secretion, folding, disulfide-bond formation, and post-translational processing for complex eukaryotic proteins. The expression construct should integrate the signal sequence, target boundaries, fusion partner, linker, orientation, and any cleavage site required for the intended product.

Define the product before selecting a partner

Clarify whether the final material should retain the partner or represent the target protein after cleavage. Define required activity, oligomeric state, purification route, analytical comparators, and in vivo or in vitro use before construct design begins.

Fc Fusion Protein Expression

Fc-fusion proteins join a protein or peptide to an immunoglobulin Fc domain. Fc can increase apparent molecular size, support affinity purification, and engage the neonatal Fc receptor, FcRn, which may contribute to extended circulation. Actual pharmacokinetic behavior remains molecule-dependent and should be evaluated for the specific construct. [3-5]

Fc-mediated dimerization may be useful for some targets and undesirable for others. Fc receptor or effector interactions may also matter to the intended application. Selection should account for valency, target biology, glycosylation, assay format, and the desired product profile.

Molecular representation of an Fc fusion protein

Selecting Fc or Human Serum Albumin as a Fusion Partner

Partner	When to consider it	Potential value	Design consideration
Fc	Projects that may benefit from FcRn engagement, Fc-based purification, increased size, or Fc-mediated dimerization	May support circulation exposure and a defined affinity-purification route	Valency, Fc receptor interactions, glycosylation, and target function require evaluation
Human serum albumin, HSA	Projects seeking an albumin-based size and recycling strategy without an Fc domain	May support solubility and circulation exposure through albumin biology	Placement and steric effects can influence target activity; purification strategy differs from Fc
Small affinity or detection tag	Projects prioritizing purification or detection with minimal added mass	Can simplify recovery or analytical tracking	May not provide the solubility or exposure effects associated with larger partners

Fc and HSA are both associated with FcRn biology, but their molecular behavior and construct effects differ. Candidate formats should be compared for expression, product quality, activity, and any required in vivo property rather than treated as interchangeable. [3-5]

Fusion Protein Placement: N-Terminus or C-Terminus

A fusion partner may be placed at the N-terminus or C-terminus of the protein of interest. Orientation can affect secretion, folding, domain accessibility, oligomerization, proteolysis, and activity. If either terminus participates in the target’s mechanism or binding interface, the opposite orientation may be a more appropriate starting point.

Placement	When to consider it	Potential value	Risk to evaluate
N-terminal fusion	Target C-terminus should remain unobstructed; signal sequence and secretion design are compatible	May support secretion or expose the target C-terminus	Can alter the mature N-terminus or interfere with N-terminal function
C-terminal fusion	Target N-terminus should remain native or functionally accessible	Preserves the target N-terminus	Can interfere with C-terminal motifs, binding, or processing
Both orientations in a construct panel	Terminal sensitivity is uncertain or activity data are limited	Provides empirical evidence for orientation selection	Requires matched expression and quality assessment

Multicolor molecular ribbon structure used to illustrate fusion protein placement

Linker and Cleavage-Site Design

A linker can provide separation between the fusion partner and protein of interest. Flexible, rigid, and cleavable linkers serve different purposes, and linker composition or length can affect folding, accessibility, stability, and function. [1]

When a protease-cleavage site is appropriate

A defined cleavage site can enable removal of the partner during purification. The protease should be sufficiently selective under conditions compatible with the target. Consider unintended cleavage sites, residual protease, cleavage efficiency, the residues left on the target, and the need to separate the released partner from the product. [1]

Fusion Protein Removal Following Mammalian Expression

Partner removal may be appropriate when the fusion increases expression or solubility but interferes with biochemical, structural, or functional studies. It may also be required when the intended product is the unfused target.

Removal adds unit operations and may reduce recovery, so the decision should be tied to a defined benefit. Compare retained-fusion and cleaved material when feasible, then assess identity, purity, aggregation, and target function.

Decision	When it fits	Potential value	Practical tradeoff
Retain the fusion partner	Partner is compatible with the required activity and final format	Simpler process with fewer separation steps	Partner-related effects remain part of the product
Remove after purification	Partner assists expression or capture but interferes with the intended assay or structure	Produces a target closer to the unfused form	Cleavage and repurification may reduce recovery or introduce heterogeneity
Evaluate both formats	The impact of the partner is uncertain	Direct evidence for the final-format decision	Requires parallel characterization and material planning

A Practical Construct-Screening Workflow

Define the intended final product, assay, and functional requirements.

Choose candidate partners based on expression, purification, activity, and in vivo needs.

Design N-terminal, C-terminal, or both orientations when terminal sensitivity is uncertain.

Select a linker and include a cleavage site only when removal supports the final product strategy.

Express candidates under matched mammalian-cell conditions.

Compare recovery, purity, integrity, aggregation, and function.

If removal is planned, evaluate cleavage efficiency, repurification, recovery, and the activity of the cleaved target.

Advance the format that best satisfies the fit-for-use criteria.

Frequently Asked Questions

What is a fusion protein?

A fusion protein is a recombinant protein in which two or more coding sequences are joined so the cell produces one polypeptide containing the linked components.

What is Fc fusion protein expression?

Fc fusion protein expression is the production of a target protein joined to an immunoglobulin Fc domain. The Fc may support purification, molecular size, dimerization, or FcRn-associated circulation behavior.

How are fusion proteins expressed in mammalian cells?

The target, partner, linker, signal sequence, placement, and any cleavage site are encoded in one expression construct, introduced into mammalian cells, and evaluated through matched expression and product-quality assays.

Should an Fc fusion be placed at the N-terminus or C-terminus?

Placement depends on terminal function, secretion design, domain accessibility, folding, and activity. When the effect is uncertain, compare both orientations under matched conditions.

When should a fusion partner be removed?

Consider removal when the partner interferes with the intended biochemical, structural, functional, or final-product requirements. Retain it when it is compatible with the intended use and simplifies the process.

Why is a linker used in a fusion protein?

A linker separates the partner and target domains and can influence folding, accessibility, and function. Flexible, rigid, or cleavable linkers should be chosen for the specific design objective.

Is human serum albumin the same as an Fc fusion partner?

No. HSA and Fc are distinct protein partners with different structures, interactions, and purification considerations, although both may be considered in half-life-oriented fusion strategies.

Discuss Your Mammalian Fusion Protein Project

TrueCourse can help connect construct design, partner selection, mammalian expression screening, purification, cleavage, and analytical characterization to the intended use of a fusion protein.

References

Peer-reviewed sources supporting the scientific context:

1. Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Advanced Drug Delivery Reviews. 2013;65(10):1357-1369. doi:10.1016/j.addr.2012.09.039. Source

2. Yu K, Liu C, Kim BG, Lee DY. Synthetic fusion protein design and applications. Biotechnology Advances. 2015;33(1):155-164. doi:10.1016/j.biotechadv.2014.11.001. Source

3. Wu B, Sun YN. Pharmacokinetics of peptide-Fc fusion proteins. Journal of Pharmaceutical Sciences. 2014;103(1):53-64. doi:10.1002/jps.23783. Source

4. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1. Journal of Immunology. 2010;184(4):1968-1976. doi:10.4049/jimmunol.0903296. Source

5. Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29:215-239. doi:10.1007/s40259-015-0133-6. Source

Share this insight